Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued on Monday. They currently have a $96.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential downside of 2.79% from the stock’s current price.
SRPT has been the topic of a number of other reports. Credit Suisse Group reiterated a “hold” rating and issued a $81.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, March 12th. Leerink Swann lifted their price target on Sarepta Therapeutics from $88.00 to $121.00 and gave the company an “outperform” rating in a research report on Tuesday, May 15th. BidaskClub lowered Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 29th. Goldman Sachs Group lifted their price target on Sarepta Therapeutics from $84.00 to $127.00 and gave the company a “buy” rating in a research report on Friday, May 18th. Finally, SunTrust Banks lifted their price target on Sarepta Therapeutics to $95.00 and gave the company a “buy” rating in a research report on Friday, March 16th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $92.18.
Shares of SRPT stock opened at $98.76 on Monday. The company has a market capitalization of $6.40 billion, a PE ratio of -60.22 and a beta of 1.35. Sarepta Therapeutics has a fifty-two week low of $31.23 and a fifty-two week high of $100.30. The company has a debt-to-equity ratio of 0.55, a quick ratio of 12.28 and a current ratio of 13.37.
A number of large investors have recently made changes to their positions in SRPT. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Sarepta Therapeutics by 39.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 977 shares during the last quarter. Prentiss Smith & Co. Inc. purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $199,000. Arrowstreet Capital Limited Partnership purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $217,000. Aperio Group LLC purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $219,000. Finally, Bayesian Capital Management LP purchased a new position in Sarepta Therapeutics during the first quarter valued at $221,000. Institutional investors and hedge funds own 86.55% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.